Effect of hydroxychloroquine on angiographic progression in routine treatment of Takayasu arteritis

References

• Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. J Clin Pathol. 2002;55(7):481–6.
   PubMed Web of Science ®Google Scholar
• Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2018;202079:19–30.
   Google Scholar
• Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018;77(3):348–54.
   PubMed Web of Science ®Google Scholar
• Bredemeier M, Rocha CM, Barbosa MV, Pitrez EH. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol. 2012;30:S98–S100.
   PubMed Web of Science ®Google Scholar
• Sun Y, Ma L, Ji Z, Zhang Z, Chen H, Liu H, et al. Value of whole-body contrast-enhanced magnetic resonance angiography with vessel wall imaging in quantitative assessment of disease activity and follow-up examination in Takayasu's arteritis. Clin Rheumatol. 2016;35(3):685–93.
   PubMed Web of Science ®Google Scholar
• Comarmond C, Biard L, Lambert M, Mekinian A, Ferfar Y, Kahn JE, et al. Long-term outcomes and prognostic factors of complications in Takayasu Arteritis: a multicenter study of 318 patients. Circulation. 2017;136(12):1114–22.
   PubMed Web of Science ®Google Scholar
• Chen R, Sun Y, Cui X, Ji Z, Kong X, Wu S, et al. Autophagy promotes aortic adventitial fibrosis via the IL-6/Jak1 signaling pathway in Takayasu's arteritis. J Autoimmun. 2019;99:39–47.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 2017;16(3):411–9.
   PubMed Web of Science ®Google Scholar
• Penn SK, Kao AH, Schott LL, Elliott JR, Toledo FG, Kuller L, et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2010;37(6):1136–42.
   PubMed Web of Science ®Google Scholar
• Trnavsky K, Gatterova J, Linduskova M, Peliskova Z. Combination therapy with hydroxychloroquine and methotrexate in rheumatoid arthritis. Z Rheumatol. 1993;52:292–6.
   PubMed Web of Science ®Google Scholar
• Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129–34.
   PubMed Web of Science ®Google Scholar
• Hata A, Noda M, Moriwaki R, Numano F. Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol. 1996;54 (Suppl):S155–S63.
   PubMedGoogle Scholar
• Russo RAG, Katsicas MM. Takayasu arteritis. Front Pediatr. 2018;6:1–17.
   PubMed Web of Science ®Google Scholar
• Haładyj E, Sikora M, Felis-Giemza A, Olesińska M. Antimalarials - are they effective and safe in rheumatic diseases? Reumatologia. 2018;56(3):164–73.
   PubMedGoogle Scholar
• Oikarinen A. Hydroxychloroquine induces autophagic cell death of human dermal fibroblasts: implications for treating fibrotic skin diseases. J Invest Dermatol. 2009;129(10):2333–5.
   PubMed Web of Science ®Google Scholar
• Ramser B, Kokot A, Metze D, Weiss N, Luger TA, Bohm M. Hydroxychloroquine modulates metabolic activity and proliferation and induces autophagic cell death of human dermal fibroblasts. J Invest Dermatol. 2009;129(10):2419–26.
   PubMed Web of Science ®Google Scholar
• Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema K-J, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;14(8):1435–55.
   PubMed Web of Science ®Google Scholar
• Manning EP, Losier A, Emeagwali N, Ryu C, Honiden S. New applications of old drugs as novel therapies in idiopathic pulmonary fibrosis. Metformin, hydroxychloroquine, and thyroid hormone. Am J Respir Crit Care Med. 2019;199(12):1561–3.
   PubMedGoogle Scholar
• Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–45.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Matsuoka N, Temmoku J, Furuya MY, Asano T, Sato S, et al. Hydroxychloroquine inhibits IL-1β production from amyloid-stimulated human neutrophils. Arthritis Res Ther. 2019;21(1):250.
   PubMed Web of Science ®Google Scholar
• Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23(5):231–69.
   PubMed Web of Science ®Google Scholar
• An J, Minie M, Sasaki T, Woodward JJ, Elkon KB. Antimalarial drugs as immune modulators: new mechanisms for old drugs. Annu Rev Med. 2017;68:317–30.
   PubMed Web of Science ®Google Scholar
• Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum. 1993;23(2 Suppl 1):82–91.
   PubMed Web of Science ®Google Scholar
• Yang M, Cao L, Xie M, Yu Y, Kang R, Yang L, et al. Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis. Biochem Pharmacol. 2013;86(3):410–8.
   PubMed Web of Science ®Google Scholar
• Oh S, Shin JH, Jang EJ, Won HY, Kim HK, Jeong MG, et al. Anti-inflammatory activity of chloroquine and amodiaquine through p21-mediated suppression of T cell proliferation and Th1 cell differentiation. Biochem Biophys Res Commun. 2016;474(2):345–50.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, et al. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol. 2015;67(5):1353–60.
   PubMed Web of Science ®Google Scholar
• Regnier P, Le Joncour A, Maciejewski-Duval A, Desbois AC, Comarmond C, Rosenzwajg M, et al. Targeting JAK/STAT pathway in Takayasu's arteritis. Ann Rheum Dis. 2020;79(7):951–9.
   PubMed Web of Science ®Google Scholar
• Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007;30(4):297–308.
   PubMed Web of Science ®Google Scholar
• Levy RA, Vilela VS, Cataldo MJ, Ramos RC, Duarte JL, Tura BR, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10(6):401–4.
   PubMed Web of Science ®Google Scholar
• Kaplan YC, Ozsarfati J, Nickel C, Koren G. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;81(5):835–48.
   PubMed Web of Science ®Google Scholar
• Sperber K, Hom C, Chao CP, Shapiro D, Ash J. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J. 2009;7:9.
   PubMed Web of Science ®Google Scholar
• Kong X, Ma L, Ji Z, Dong Z, Zhang Z, Hou J, et al. Pro-fibrotic effect of IL-6 via aortic adventitial fibroblasts indicates IL-6 as a treatment target in Takayasu arteritis. Clin Exp Rheumatol. 2018;36(1):62–72.
   PubMed Web of Science ®Google Scholar
• Chen XZ, Yao WM, Zhang G, Ye HL, Chen L, Zhang FC. Enhanced autophagic flux contributes collagen production in hepatic stellate cells involving TGFbeta1/Smad pathway signaling. Faseb J. 2013;27:1161–3.
   Web of Science ®Google Scholar
• Crotzer VL, Blum JS. Autophagy and its role in MHC-mediated antigen presentation. J Immunol. 2009;182(6):3335–41.
   PubMed Web of Science ®Google Scholar
• Katz Y, Revel M, Strunk RC. Interleukin 6 stimulates synthesis of complement proteins factor B and C3 in human skin fibroblasts. Eur J Immunol. 1989;19(6):983–8.
   PubMed Web of Science ®Google Scholar
• Kiprian D, Czarkowska-Paczek B, Wyczalkowska-Tomasik A, Fuksiewicz M, Kotowicz B, Paczek L. Radiotherapy and radiochemotherapy increase serum levels of pro-inflammatory interleukin-6 and C-reactive protein in patients with head and neck cancers. Transl Cancer Res. 2018;7(1):41–7.
   Web of Science ®Google Scholar
• Holven KB, Aukrust P, Retterstol K, Hagve TA, Mørkrid L, Ose L, et al. Increased levels of C‐reactive protein and interleukin‐6 in hyperhomocysteinemic subjects. Scand J Clin Lab Inv. 2006;66(1):45–54.
   PubMed Web of Science ®Google Scholar